Precision Medicine in Oncology®

Udai Banerji, discusses the rationale for a phase 1 trial, the potential implications of these data, and future studies in development.

David P. Carbone, MD, PhD, discusses a study evaluating acquired resistance to osimertinib in non–small cell lung cancer.

Kevin Hughes, MD, highlights the need for widespread implementation of genetic testing in breast cancer.

A minimally invasive blood test has been found to be feasible to safely detect several types of cancers in patients without a history of malignancies, enabling treatment with curative intent in a subset of individuals.

The United Kingdom’s National Institute for Health and Care Excellence has recommended larotrectinib for the treatment of adult and pediatric patients with advanced NTRK fusion–positive solid tumors.

The FDA has approved FoundationOne CDx as the registrational companion diagnostic for pemigatinib, which the agency recently approved for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic FGFR2+ cholangiocarcinoma.

Hatim Husain, MD, discusses the evolution of liquid biopsies in lung cancer.

Kathryn E. Hudson, MD, discusses the utility of liquid biopsy in lung cancer.

Comprehensive genomic profiling can be successfully performed in the majority of patients with sarcoma, depending on the tumor location and tissue subtype, which can impact treatment decisions and patient outcomes.

Joyce A. O'Shaughnessy, MD, discusses the design and findings of the plasmaMATCH trial and ongoing research with targeted therapy in breast cancer.

Ibrahim S. Alshaygy, MD, MSC, discusses precision medicine research in tenosynovial giant cell tumor.

Anastasios (Tassos) Dimou, MD, discusses the progress made in the treatment of patients with ALK-positive lung cancer.

Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors in patients with hormone receptor–positive metastatic breast cancer.

Amplicon-based liquid biopsy can detect ALK/ROS1 fusions in TKI-naïve patients with non–small cell lung cancer and allows for the identification of resistance mutations in those treated with TKIs.